Financial & Tax Architects LLC Acquires 2,347 Shares of Johnson & Johnson (NYSE:JNJ)

Financial & Tax Architects LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,533 shares of the company's stock after acquiring an additional 2,347 shares during the quarter. Johnson & Johnson comprises about 1.5% of Financial & Tax Architects LLC's holdings, making the stock its 28th largest position. Financial & Tax Architects LLC's holdings in Johnson & Johnson were worth $6,006,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the stock. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $31,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares during the last quarter. Finally, Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter worth about $40,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. StockNews.com lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target for the company. Finally, Wells Fargo & Company upped their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $174.29.

Johnson & Johnson Stock Down 0.5 %

JNJ traded down $0.74 during midday trading on Monday, hitting $147.03. 10,678,393 shares of the company's stock traded hands, compared to its average volume of 6,880,262. The company has a market cap of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock's fifty day simple moving average is $148.51 and its 200-day simple moving average is $156.10. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.